Skip to main content
Premium Trial:

Request an Annual Quote

Nuclea Biotechnologies Attracts $4.2M in Series D Round

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies today said that it raised $4.2 million in its Series D round. The Pittsfield, Mass.-based company added that it plans to close the $5 million round on May 31.

Proceeds from today's raise will be directed toward the commercialization of Nuclea's Fatty Acid Synthase assays and other clinical assays, including the in vitro diagnostic HER-2/neu ELISA assay, the basis of the recent deal between Nuclea and biomarker-based test development company Wilex.

Nuclea also develops gene and protein expression-based assays.

The new funds will go toward marketing, strengthening strategic partnerships, and building relationships with hospitals, the company said.

"Now, we move from the development stage into the commercialization stage," Nuclea President and CEO Patrick Muraca said in a statement. "This is a key milestone in the trajectory of Nuclea's growth; all of our previous successes were working toward this transition into the commercialization of our diagnostic assays."

Since the company's founding in 2005, it has raised $40.3 million, Nuclea said. In February, it raised $1.1 million toward a targeted $2.5 million financing round, though it is unclear whether that is connected to the round announced today. Last summer, the firm raised $5 million as part of a Series C round, with the goal of raising $10 million.

The Scan

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.

Active Lifestyle Linked to Type 2 Diabetes Prevention in People at High Genetic Risk

A study in the British Journal of Sports Medicine shows that an active lifestyle goes a long way in type 2 diabetes prevention.

Beneficial, Harmful Effects of Introgression Between Wild and Domesticated European Grapes

A paper in PNAS shows that European wild grapevines were an important resource for improving the flavor of cultivated wine grapes.

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.